The persisting challenge of selective and specific proteasome inhibition.


Since the discovery of the proteasome and its structure elucidation intensive research programs in academic institutions and pharmaceutical industries led to identification of a wide spectrum of synthetic and natural small proteasomal inhibitors. Activity studies with these small molecules helped to deeply understand the complex biochemical organization and functioning of the proteasome. The new structural and biochemical insights placed the proteasome as an important anti-cancer drug target, as revealed by the dipeptide boronate proteasome inhibitor, bortezomib, which is currently used for treatment of multiple myeloma. Serious side effects and partial cell resistance against bortezomib demand creation and discovery of new improved generations of more specific and potent proteasomal inhibitors.

DOI: 10.1002/psc.1107
Citations per Year

83 Citations

Semantic Scholar estimates that this publication has 83 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Groll2009ThePC, title={The persisting challenge of selective and specific proteasome inhibition.}, author={Michael Groll and Robert Huber and Luis Moroder}, journal={Journal of peptide science : an official publication of the European Peptide Society}, year={2009}, volume={15 2}, pages={58-66} }